[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-12-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1202 |
| _version_ | 1831648730334363648 |
|---|---|
| author | Fabio Tarsetti Giuseppe Tarantino Piergiorgio Mosca Emidio Scarpellini Giammarco Fava |
| author_facet | Fabio Tarsetti Giuseppe Tarantino Piergiorgio Mosca Emidio Scarpellini Giammarco Fava |
| author_sort | Fabio Tarsetti |
| collection | DOAJ |
| description | BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir.
MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered.
RESULTS: After 12 weeks of therapy, entecavir and tenofovir lead to HBV-DNA negativization in 44% and 62% of patients, respectively. A case of viral seroconversion for HBeAg and HBsAg was evident in entecavir group, while no cases were registered in tenofovir group. After 12 weeks, 11% of entecavir treated patients and 37% of tenofovir treated patients showed normalization of transaminases.
DISCUSSION: Tenofovir seems to exert a better viral replication inhibition (though not statistically significant) and to show transaminases improvement in comparison with entecavir, which, in turn, results more effective in HBeAg/HBsAg seroconversion. Both drugs have a high safety profile in terms of side effects.
[Article in Italian] |
| first_indexed | 2024-12-19T14:36:51Z |
| format | Article |
| id | doaj.art-110147a54b424430b10ade550ead6b6e |
| institution | Directory Open Access Journal |
| issn | 1973-4832 2283-3137 |
| language | English |
| last_indexed | 2024-12-19T14:36:51Z |
| publishDate | 2015-12-01 |
| publisher | SEEd |
| record_format | Article |
| series | Clinical Management Issues |
| spelling | doaj.art-110147a54b424430b10ade550ead6b6e2022-12-21T20:17:13ZengSEEdClinical Management Issues1973-48322283-31372015-12-01949510010.7175/cmi.v9i4.12021142[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]Fabio Tarsetti0Giuseppe Tarantino1Piergiorgio Mosca2Emidio Scarpellini3Giammarco Fava4SOD Malattie dell’Apparato digerente, Endoscopia Digestiva e Malattie Infiammatorie Croniche Intestinali. Azienda Ospedaliera Universitaria “Ospedali Riuniti”, AnconaSOD Clinica di Gastroenterologia, Epatologia ed Endoscopia d’Urgenza, Azienda Ospedaliera Universitaria, “Ospedali Riuniti”, AnconaSOD Malattie dell’Apparato digerente, Endoscopia Digestiva e Malattie Infiammatorie Croniche Intestinali. Azienda Ospedaliera Universitaria “Ospedali Riuniti”, AnconaSOD Malattie dell’Apparato digerente, Endoscopia Digestiva e Malattie Infiammatorie Croniche Intestinali. Azienda Ospedaliera Universitaria “Ospedali Riuniti”, AnconaSOD Malattie dell’Apparato digerente, Endoscopia Digestiva e Malattie Infiammatorie Croniche Intestinali. Azienda Ospedaliera Universitaria “Ospedali Riuniti”, AnconaBACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir. MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered. RESULTS: After 12 weeks of therapy, entecavir and tenofovir lead to HBV-DNA negativization in 44% and 62% of patients, respectively. A case of viral seroconversion for HBeAg and HBsAg was evident in entecavir group, while no cases were registered in tenofovir group. After 12 weeks, 11% of entecavir treated patients and 37% of tenofovir treated patients showed normalization of transaminases. DISCUSSION: Tenofovir seems to exert a better viral replication inhibition (though not statistically significant) and to show transaminases improvement in comparison with entecavir, which, in turn, results more effective in HBeAg/HBsAg seroconversion. Both drugs have a high safety profile in terms of side effects. [Article in Italian]https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1202HBVEntecavirTenofovirSeroconversion |
| spellingShingle | Fabio Tarsetti Giuseppe Tarantino Piergiorgio Mosca Emidio Scarpellini Giammarco Fava [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] Clinical Management Issues HBV Entecavir Tenofovir Seroconversion |
| title | [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] |
| title_full | [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] |
| title_fullStr | [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] |
| title_full_unstemmed | [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] |
| title_short | [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience] |
| title_sort | tenofovir and entecavir for chronic hepatitis b infection treatment a single center experience |
| topic | HBV Entecavir Tenofovir Seroconversion |
| url | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1202 |
| work_keys_str_mv | AT fabiotarsetti tenofovirandentecavirforchronichepatitisbinfectiontreatmentasinglecenterexperience AT giuseppetarantino tenofovirandentecavirforchronichepatitisbinfectiontreatmentasinglecenterexperience AT piergiorgiomosca tenofovirandentecavirforchronichepatitisbinfectiontreatmentasinglecenterexperience AT emidioscarpellini tenofovirandentecavirforchronichepatitisbinfectiontreatmentasinglecenterexperience AT giammarcofava tenofovirandentecavirforchronichepatitisbinfectiontreatmentasinglecenterexperience |